Angiogenesis is important for the growth of the majority of tumor types, and therapies directed against vascular endothelial growth factor (VEGF) and its receptor VEGFR2, combined with cytotoxic agents, have been used successfully to inhibit tumor growth in various solid cancers (Hurwitz et al., 2004; Miller et al., 2007; Sandler et al., 2006). This evidence concerns the gene KDR and neoplasm.